[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.6″ _module_preset=”93af678d-99a3-440b-b0d9-3a4356a67f33″ background_color=”#1A1B4D” use_background_color_gradient=”off” background_image=”https:\/\/alzorabio.com\/wp-content\/uploads\/2025\/11\/non-profit-03.jpg” custom_margin=”||-1px||false|false” locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-4c79ba3d-a281-4fb6-9b14-02f9a4c793f2%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-688c464a-d6f2-4296-b592-395352c71c79%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-d119accd-44d7-4f2f-b9d7-599c8463324b%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-2352d280-fe84-43b1-a71e-f400c35a526a%22:%91%22background_color_gradient_stops%22%93,%22gcid-9e22d70d-67ee-4430-bed3-4bc105d4ef1e%22:%91%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Next-Generation Antibody Engineering for Alzheimer\u2019s Disease” _builder_version=”4.27.6″ _module_preset=”2129416d-05c9-4b8d-a7b3-cd707c19bf47″ title_font=”–et_global_heading_font||||||||” title_text_align=”center” title_text_color=”#D4B4F9″ title_font_size=”48px” custom_margin=”||10px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_orientation=”center” global_colors_info=”{}”]<\/p>\n
Alzora Bio is developing next-generation antibody engineering approaches designed to maintain efficacy while improving safety, expanding patient eligibility, and enabling real-world adoption.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”#approach” button_text=”Explore Our Approach” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ locked=”off” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”About” _builder_version=”4.27.6″ _module_preset=”afd460cc-f6d0-4b9d-b4be-304acb0693ae” background_color=”#FFFFFF” custom_margin=”||||false” custom_padding=”||||true|false” locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22%93,%22gcid-a78660e1-cfc7-4771-a566-6834d6a7f06a%22:%91%22background_color_gradient_stops%22%93,%22gcid-24b0db87-dafa-47d9-995f-b90181e18c52%22:%91%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.25.2″ _module_preset=”default” max_width=”900px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”About Us” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_font=”–et_global_heading_font|700||on|||||” title_text_align=”center” title_text_color=”#D4B4F9″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”d4bf98c7-0ca4-43df-b91e-5ed3c2635018″ text_font=”–et_global_body_font||||||||” text_text_color=”#1A1B4D” text_font_size=”24px” text_orientation=”center”]<\/p>\n
Alzora Bio is a research group based at the University of Southampton developing next-generation antibody approaches for Alzheimer\u2019s disease.<\/p>\n
Our work focuses on enhancing the safety profile of amyloid-targeting therapies while maintaining clinical efficacy, with the aim of expanding the treatable patient population and improving real-world adoption.<\/p>\n
As part of the ICURe Explore programme, we are engaging with industry stakeholders to understand clinical, commercial, and partnership opportunities for advancing safer Alzheimer\u2019s therapies.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ custom_padding_last_edited=”on|desktop” _builder_version=”4.27.6″ _module_preset=”default” background_color=”#1A1B4D” custom_margin=”30px||50px||false|false” custom_padding=”40px|40px|40px|40px|true|true” custom_padding_tablet=”30px|30px|30px|30px|true|true” custom_padding_phone=”20px|20px|20px|20px|true|true” border_radii=”on|30px|30px|30px|30px” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.25.2″ _module_preset=”default” background_enable_color=”off” global_colors_info=”{%22gcid-4c79ba3d-a281-4fb6-9b14-02f9a4c793f2%22:%91%22background_color%22%93}”][et_pb_heading title=”Help Shape the Future of Alzheimer\u2019s Treatment” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” title_text_color=”#FFFFFF” title_font_size=”25px” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font|300|||||||” text_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n
We are seeking insights from pharmaceutical and biotech professionals to better understand development priorities, safety considerations, and partnership opportunities in Alzheimer\u2019s treatment.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/research.typeform.com\/to\/BaOyg8Pq” url_new_window=”on” button_text=”Complete the Survey” button_alignment=”right” button_alignment_tablet=”left” button_alignment_phone=”left” button_alignment_last_edited=”on|tablet” _builder_version=”4.27.6″ _module_preset=”003de22d-416e-481c-86a7-51d2caaf0405″ button_text_size=”13px” button_text_color=”#D4B4F9″ button_border_color=”#D4B4F9″ custom_margin=”30px||||false|false” custom_margin_tablet=”30px||||false|false” custom_margin_phone=”1px||||false|false” custom_margin_last_edited=”on|phone” global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22button_text_color%22%93}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Features & Video” module_id=”approach” _builder_version=”4.27.6″ _module_preset=”afd460cc-f6d0-4b9d-b4be-304acb0693ae” background_color=”#1A1B4D” custom_margin=”0px||||false|false” custom_padding=”100px||100px||true|false” locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22%93,%22gcid-a78660e1-cfc7-4771-a566-6834d6a7f06a%22:%91%22background_color_gradient_stops%22%93,%22gcid-24b0db87-dafa-47d9-995f-b90181e18c52%22:%91%22background_color_gradient_stops%22%93}”][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.6″ _module_preset=”default” hover_enabled=”0″ locked=”off” global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”1_3″ _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Engineered Antibody Precision” use_icon=”on” font_icon=”||fa||900″ icon_color=”#1A1B4D” _builder_version=”4.27.6″ _module_preset=”e26e2c24-6c7e-4666-a99d-bf3bfa25798b” header_font=”–et_global_heading_font||||||||” header_text_color=”#1A1B4D” body_font=”–et_global_body_font||||||||” custom_margin=”||30px||false|false” locked=”off” global_colors_info=”{%22gcid-d7cd5a78-aaef-4f36-82a3-4d3706015cba%22:%91%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22%93,%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22,%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22,%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22%93}” quote_font_size_tablet=”20px” quote_font_size_phone=”16px” quote_font_size_last_edited=”on|desktop”]<\/p>\n
Our approach uses targeted antibody engineering to selectively engage certain Fc receptors, enabling effective amyloid clearance with improved safety.<\/p>\n
[\/et_pb_blurb][et_pb_button button_url=”https:\/\/alzorabio.com\/index.php\/contact-page\/” button_text=”Connect With Our Team” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ custom_css_main_element=”width: 100%” global_colors_info=”{}” button_bg_color__hover_enabled=”on|hover” button_bg_color__hover=”#1A1B4D” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.6″ _module_preset=”55f1fdbd-df3e-44c0-99ea-f56f922b4607″ background_color=”#D4B4F9″ global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#FFFFFF” icon_width=”50px” align=”left” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”||30px||false|false” global_colors_info=”{}”][\/et_pb_icon][et_pb_heading title=”Optimised Immune Engagement” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” title_text_color=”#FFFFFF” custom_margin=”||10px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”d4bf98c7-0ca4-43df-b91e-5ed3c2635018″ text_font=”–et_global_body_font||||||||”]<\/p>\n
By refining how antibodies interact with Fc-receptors, we aim to minimise neuroinflammation and reduce the incidence of ARIA-related effects seen in current therapies.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.6″ _module_preset=”default” background_image=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Antibody-Structure-1.png” custom_padding=”20px||||false|false” hover_enabled=”0″ border_radii=”on|30px|30px|30px|30px” global_colors_info=”{}” title_text=”Antibody Structure (1)” sticky_enabled=”0″][et_pb_heading title=”antibody structure” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_font=”–et_global_heading_font|700||on|||||” title_text_align=”center” title_text_color=”#D4B4F9″ title_font_size=”15px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_heading][et_pb_divider show_divider=”off” _builder_version=”4.27.6″ _module_preset=”default” height_tablet=”50vw” height_phone=”50vw” height_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/7hgVYSAo0W4?si=yUC6JwG9pJvpOrFQ” image_src=”\/\/i.ytimg.com\/vi\/p5oH02zO-RI\/hqdefault.jpg” _builder_version=”4.27.6″ _module_preset=”7044e12c-8309-4651-a22b-c4bc3dc1649b” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Programs” _builder_version=”4.27.6″ _module_preset=”c6252a93-7079-41ad-a1de-374f79e4e1ec” custom_margin=”24px||24px||true|false” locked=”off” collapsed=”on”][et_pb_row _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Strategic Applications & Value Drivers” _builder_version=”4.27.6″ _module_preset=”b561d760-fec3-4894-afcb-2b0f9eaee7ed” title_font=”–et_global_heading_font||||||||” global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Expanding-market.png” title_text=”Expanding market” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Expanding Market Opportunity” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
Safety limitations currently restrict anti-amyloid antibody therapies\u00a0 to a small subset of patients. Our approach is designed to improve tolerability, enabling access to a significantly broader patient population.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Opportunity: Up to 3x expansion in eligible population” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Scalable-delivery.png” title_text=”Scalable delivery” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Enabling Scalable Delivery” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” title_font_size=”25px” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
Intensive MRI monitoring presents a key barrier to adoption and scalability. By reducing safety-related risks, our approach may lower monitoring requirements and support more efficient deployment across healthcare systems.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Opportunity: Reduced system burden & improved scalability” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ locked=”off” global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Pipeline-potential.png” title_text=”Pipeline potential” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Unlocking Pipeline Potential” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
A safer antibody profile may enable earlier intervention, improved dosing strategies, and the re-evaluation of previously limited or discontinued therapeutic candidates across development pipelines and clinical programmes.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Opportunity: Enhanced efficacy & lifecycle extension” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ locked=”off” global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Call to Action” _builder_version=”4.27.6″ _module_preset=”11146adb-762a-47ad-b42a-e296fc724659″ background_color=”#1A1B4D” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Connect with our team to explore partnership opportunities and learn more about our antibody engineering approach.” _builder_version=”4.27.6″ _module_preset=”b561d760-fec3-4894-afcb-2b0f9eaee7ed” title_font=”–et_global_heading_font||||||||” title_text_align=”center” title_text_color=”#FFFFFF” title_font_size=”35px” global_colors_info=”{}”][\/et_pb_heading][et_pb_button button_url=”https:\/\/alzorabio.com\/index.php\/contact-page\/” button_text=”Contact Our Team” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ global_colors_info=”{}” button_bg_color__hover_enabled=”on|hover” button_bg_color__hover=”#1A1B4D” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Alzora Bio is developing next-generation antibody engineering approaches designed to maintain efficacy while improving safety, expanding patient eligibility, and enabling real-world adoption.Alzora Bio is a research group based at the University of Southampton developing next-generation antibody approaches for Alzheimer\u2019s disease. Our work focuses on enhancing the safety profile of amyloid-targeting therapies while maintaining clinical efficacy, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-85965","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/comments?post=85965"}],"version-history":[{"count":14,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85965\/revisions"}],"predecessor-version":[{"id":86026,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85965\/revisions\/86026"}],"wp:attachment":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/media?parent=85965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}